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Abstract
Background: Metformin, an FDA-approved drug for the treatment of Type II diabetes, has emerged as a promising
anti-cancer agent. Other biguanide analogs, including buformin and phenformin, are suggested to have similar
properties. Although buformin was shown to reduce mammary tumor burden in carcinogen models, the anti-cancer
effects of buformin on different breast cancer subtypes and the underlying mechanisms remain unclear. Therefore, we
aimed to investigate the effects of buformin on erbB-2-overexpressing breast cancer with in vitro and in vivo models.
Methods: MTT, cell cycle, clonogenic/CFC, ALDEFLUOR, tumorsphere, and Western blot analyses were used to
determine the effects of buformin on cell growth, stem cell populations, stem cell-like properties, and signaling
pathways in SKBR3 and BT474 erbB-2-overexpressing breast cancer cell lines. A syngeneic tumor cell transplantation
model inoculating MMTV-erbB-2 mice with 78617 mouse mammary tumor cells was used to study the effects of
buformin (1.2 g buformin/kg chow) on tumor growth in vivo. MMTV-erbB-2 mice were also fed buformin for 10 weeks,
followed by analysis of premalignant mammary tissues for changes in morphological development, mammary
epithelial cell (MEC) populations, and signaling pathways.
Results: Buformin significantly inhibited SKBR3 and BT474 cell growth, and in vivo activity was demonstrated by
considerable growth inhibition of syngeneic tumors derived from MMTV-erbB-2 mice. In particular, buformin suppressed
stem cell populations and self-renewal in vitro, which was associated with inhibited receptor tyrosine kinase (RTK) and
mTOR signaling. Consistent with in vitro data, buformin suppressed mammary morphogenesis and reduced cell
proliferation in MMTV-erbB-2 mice. Importantly, buformin decreased MEC populations enriched with mammary
reconstitution units (MRUs) and tumor-initiating cells (TICs) from MMTV-erbB-2 mice, as supported by impaired
clonogenic and mammosphere formation in primary MECs. We further demonstrated that buformin-mediated in vivo
inhibition of MEC stemness is associated with suppressed activation of mTOR, RTK, ER, and β-catenin signaling pathways.
Conclusions: Overall, our results provide evidence for buformin as an effective anti-cancer drug that selectively targets
TICs, and present a novel prevention and/or treatment strategy for patients who are genetically predisposed to
erbB-2-overexpressing breast cancer.
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Background
Breast cancer prevention and treatment are often met with
significant challenges due to the heterogeneity of mammary
tumors that contribute to poor prognosis. For instance,
cancer preventatives, like tamoxifen for estrogen receptor-
positive (ER+) breast cancers, have shown clinical efficacy;
yet, the prevention of ER- breast cancers, including the
erbB-2-overexpressing subtype, remains elusive [1, 2].
Consequently, the search for novel strategies to prevent
and treat breast cancer has expanded over the past decade
to drugs that have shown promise in other disease models
and other cancer sites. In particular, metformin, a biguanide
drug commonly prescribed to treat Type II diabetes in
humans, has demonstrated anti-cancer effects, which was
published in an earlier milestone report by Evans et al.
(2005) showing that metformin significantly reduced the
risk of developing multiple types of cancer in patients with
diabetes [3]. Thereafter, other studies corroborated that
metformin lowered breast cancer risk [4]. Breast cancers,
including the erbB-2-overexpressing subtype, are often as-
sociated with morbidity and poor clinical outcomes; there-
fore, the identification and development of effective erbB-2-
overexpressing breast cancer prevention and treatment op-
tions are crucial [5–7].
In regard to the need for breast cancer preventatives,
many preclinical studies and clinical trials have been initi-
ated to determine the underlying mechanisms involved in
the reported anti-cancer effects of metformin and to develop
metformin as a novel breast cancer preventative strategy by
optimizing treatment doses and conditions. As such, pre-
clinical studies have explored the preventative effects of met-
formin in various cell and animal models of cancer. In
prostate cancer LNCaP and PC-3 cell lines, metformin has
been shown to induce anti-cancer effects through the inhib-
ition of cell growth and the activation of AMPK-dependent
and MAPK-mediated apoptosis [8–10]. Similarly, metformin
has previously been reported to induce MAPK-mediated
apoptosis in addition to GADD153-mediated apoptosis in
A549 and NCI-H1299 human lung cancer cell lines [11].
Breast cancer has also been the focus of many studies deter-
mining the efficacy and underlying mechanism of the cancer
preventative activities of metformin. In breast cancer cell
lines, including MCF-7, MCF-10A, and MDA-MB-231 (p53
wt) cells, metformin stimulated the inhibition of cell prolif-
eration and the induction of apoptosis, which were found to
be dependent on AMPK and p53 status in the cells [8, 12].
As such, data from our lab have previously reported that
metformin can significantly inhibit growth of syngeneic
erbB-2-overexpressing mammary tumors from MMTV-
erbB-2 transgenic mice inoculated with 78617 cells [13].
Results from preclinical cell and animals models testing the
anti-cancer effects of metformin are further reflected in
clinical trials. A meta-analysis of 11 clinical studies testing
the anti-cancer effects of metformin determined that
metformin reduced colon, prostate, and breast cancer risk
by up to 31%, collectively [14].
Although metformin has demonstrated substantial clinical
cancer protective benefits, the mechanisms behind the anti-
cancer properties of metformin are not completely under-
stood. As a Type II diabetes therapeutic, metformin disrupts
the Warburg effect and reduces glucose output by the liver
and circulating insulin levels [15]. These effects on glucose
metabolism are also demonstrated in non-diabetic models
alongside a characteristic upregulation of the energy sensor
AMPK, through the inhibition of the mitochondrial com-
plex I [4, 16–18]. The activation/phosphorylation of AMPK
subsequently inhibits proliferative cellular responses associ-
ated with the mTOR signaling pathway [4, 18]. In particular,
metformin blocked mTOR-dependent translation, which is
essential for the regulation of cell growth, survival, and
angiogenesis, in MCF-7 breast cancer cells [19, 20]. Alterna-
tively, Ben Sahra et al. (2011) reported that metformin can
induce AMPK-independent cellular responses under
hypoxic conditions in LNCaP prostate cancer cells, includ-
ing REDD1-mediated mTOR inhibition and subsequent cell
cycle arrest [21]. Moreover, the effects of metformin on glu-
cose metabolism and mTOR signaling inhibition are also
implicated in cancer stem cell (CSC) regulation as previously
shown in syngeneic tumor, xenograft tumor, and transgenic
mouse models of breast cancer [13, 22, 23]. CSCs contribute
to tumor development because of increased proliferative
and self-renewal capabilities [24]. Metformin further inhibits
cancer cell proliferation through blockage of the IGF/IGF-
1R signaling pathway, as shown in PC-3 prostate cancer
cells, MKN1, MKN45, and MKN74 gastric cancer cells, and
SKBR3 and BT474 breast cancer cells [25–27].
Based on the presented studies showing the anti-cancer
effects of metformin across a range of cell, animal, and
human cancer models, metformin is a promising cancer
preventative drug. Nevertheless, several challenges still re-
main. To this end, the specific mechanisms of action, clinical
efficacy, and exploration of metformin analogs warrants fur-
ther investigation. In regards to analogs with structural and
functional similarities to metformin, recent studies using
phenformin and buformin indicate increased bioactivity and
anti-cancer effects than metformin [28–30]. Similar to met-
formin, buformin also has demonstrated anti-cancer proper-
ties through the induction of cell cycle arrest, apoptosis, and
reduced cell adhesion and migration in ECC-1 and Ishikawa
endometrial cell lines [31]. In these cells, buformin exhibited
a lower IC50 value than metformin as well. Furthermore,
Zhu et al. (2015) revealed that buformin (7.6 mM/kg)
decreased tumor incidence and burden to a greater extent
than metformin (9.3 mM/kg) and phenformin (5 mM/kg) in
a 1-methyl-1-nitrosourea (MNU)-induced mammary car-
cinogenesis model using Sprague–Dawley rats [30]. Despite
buformin being withdrawn from the market due to toler-
ance concerns, these promising reports detailing the anti-
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cancer properties of buformin in vitro and in vivo indicate
that further studies into the efficacy and mechanisms of
buformin are necessary in order to determine a dose that
will maintain anti-cancer benefits while increasing drug
tolerance.
Our lab recently studied the cancer preventative effects
of metformin treatment in cell and animal models of erbB-
2-overexpressing breast cancer [13]. We found that metfor-
min significantly inhibited cell proliferation and the stem-
ness of erbB-2-overexpressing breast cancer cell lines.
Likewise, metformin inhibited tumor growth in MMTV-
erbB-2 transgenic mice through the targeting of the CSCs
[13]. Due to the limited number of studies on the anti-
cancer efficacy of buformin, the effects on specific, refrac-
tory breast cancer subtypes, like erbB-2-positive breast
cancer, remains to be explored. To this end, using the well-
established MMTV-erbB-2 mouse model in our current
study, we found that buformin inhibits cell proliferation,
cell cycle, and CSC self-renewal properties in erbB-2-
overexpressing breast cancer cells. These findings also
translated to a syngeneic tumor transplantation model in
MMTV-erbB-2 mice that indicated buformin, when admin-
istered in the diet, inhibited tumor growth. Furthermore,
we demonstrated that buformin diet produced significant
inhibition of mammary morphogenesis and CSC popula-
tions in premalignant mammary tissues from MMTV-
erbB-2 mice. Taken together, our data provide evidence for
buformin as an effective anti-cancer drug, especially in
patients at a high risk for developing erbB-2-overexpressing
breast cancers, and may ultimately have a significant impact
on breast cancer prevention.
Methods
Antibodies and reagents
Buformin was purchased from Wako Pure Chemical
Industries (Osaka, Japan). Primary antibodies against
AMPK, p-AMPK, mTOR, p-mTOR, p70S6K, p-p70S6K,
4EBP1, p-4EBP1, IRS, p-IRS, IGF1R, p-IGF1R, p-erbB-2,
Akt, p-Akt, p-Erk1/2, p-Stat3, p-ER, β-catenin, Oct4A, and
Notch were purchased from Cell Signaling (Danvers, MA).
Antibodies against IGF1Rα/β, Erk, Stat3, ER, Cyclin D1,
and β-actin were ordered from Santa Cruz Biotechnology
(Santa Cruz, CA). erbB-2 and active β-catenin antibodies
were purchased from EMD Millipore (Billerica, CA).
Cell culture and treatment
Breast cancer cell lines used in these studies, including
SKBR3 and BT474 cells from ATCC (Manassas, VA) and
mammary tumor-derived 78617 cells, were maintained
in DMEM/F-12 culture medium supplemented with 10%
fetal bovine serum (FBS), 100 μg/ml penicillin, and
100 μg/ml streptomycin at 37 °C in an incubator with a
humidified 5% CO2 atmosphere. The medium was re-
placed and cells were treated with buformin 24 h after
seeding. The 78617 breast cancer cell line was estab-
lished in our lab from FVB/N-Tg/MMTV-erbB-2
(MMTV-erbB-2) transgenic mouse mammary tumors as
previously reported [32].
Cell viability assay
SKBR3 and BT474 cells were plated (1 × 103 cells/well)
in 96-well plates for 24 h. Then the cells were incubated
in indicated doses of buformin for 5 days. Following drug
treatment, the cells were incubated at 37 °C for 4 h in 3-
(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT). The medium was removed and 50 μl DMSO
was added to each well and incubated at room
temperature for 45 min while shaking. Absorbance was
measured using a SynergyMx microplate reader (BioTek;
Winooski, VT) to determine the viable cell fraction.
Cell cycle analysis
SKBR3 and BT474 cells were treated with indicated con-
centrations of buformin for 48 h. Then, the cells were tryp-
sinized and fixed in ice-cold 70% ethanol (added drop-wise)
at −20 °C overnight. Fixed cells were centrifuged to form a
cell pellet and the supernatant was removed. The cells were
resuspended and incubated in PBS containing 0.2% triton
X-100, 500 μg/ml RNase A, and 33 μg/ml propidium iodide
at 37 °C for 45 min. Finally, the number of cells in each
phase of the cell cycle was analyzed using fluorescence-
activated cell sorting (FACS) and ModFit software.
Clonogenic and colony-forming cell (CFC) assays
SKBR3 and BT474 cells were seeded at 1 × 103 and 2 × 103
cells/well, respectively, in 6-well plates for 24 h and then
treated with indicated doses of buformin for 14 days. The
isolated primary mammary epithelial cells (MECs) from
control-fed and buformin-fed mice were seeded at 4 × 103
cells/plate in 60 mm plates and incubated for 7 days. After
incubation, the cultured cells were washed with PBS and
stained with 0.5% crystal violet (1:1 of methanol:H2O). The
primary cells were washed with PBS, fixed with acetone:-
methanol (1:1), and stained with Wright’s Giemsa. Stained
colonies were imaged using the Nikon SMZ 745 T micro-
scope and Nikon Elements Imaging System Software. The
number of colonies with ≥ 50 cells was recorded for each
sample. All treatments were tested in at least triplicate.
Animals and buformin diet
Female MMTV-erbB-2 transgenic mice were purchased
from Jackson Laboratories (Bar Harbor, ME). All mice were
fed a standard, estrogen-free AIN-93G diet (Bio-Serv;
Flemington, NJ) until 8 weeks of age when the mice were
divided into control and experimental groups. The control
mice continued receiving the AIN-93G diets, while the
treatment group received an AIN-93G-based buformin diet
that contained 1.2 g of buformin/kg of chow (7.6 mmol
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buformin/kg of chow) [30]. Based on the assumptions that
a mouse weighing 25 g will eat approximately 6 g of chow/
day, we estimate that each mouse being fed the buformin
diet will consume 7.2 mg of buformin/day. The mice were
fed control and buformin diets for 10 weeks until the mice
reached 18 weeks of age and were euthanized for further
analysis of collected tissues. All animal procedures were
performed according to IACUC-approved protocols.
Syngeneic tumor model
8-week-old MMTV-erbB-2 mice were inoculated with a
subcutaneous injection of 78617 cells (5 × 105) in each
flank. By 6 days after inoculation with the tumor cells,
palpable tumors were formed in the mice and half of the
mice were fed the buformin diet described above, while
the remaining mice continued on the standard AIN-93G
diet. Tumors were palpated every 2 days beginning
6 days after inoculation with the tumor cells and tumor
volumes were calculated as: Volume (mm3) = (width2 ×
length)/2. On Day 18 after the initial tumor cell inocula-
tion, the mice were euthanized and the tumors were ex-
cised, weighed, and imaged.
ALDEFLUOR assay
The ALDEFLUOR kit (Stemcell Technologies; Cambridge,
MA) was used to measure aldehyde dehydrogenase 1
(ALDH1) activity in breast cancer cell lines. Cells were
treated with indicated doses of buformin for 48 h followed
by incubation with the ALDEFLUOR substrate at 37 °C for
30 min. To define the ALDEFLUOR-positive region, the
ALDH1 inhibitor, diethylaminobenzaldehyde (DEAB), was
used for negative control samples. Four replicates of control
and treated samples were analyzed with flow cytometry
using Guava EasyCyte Flow Cytometer (EMD Millipore)
and FlowJo analysis software to determine the percentage
of ALDH-positive (ALDH+) cells.
Tumorsphere and mammosphere assays
For tumorsphere assays, 78617 or BT474 cells were seeded
(800 cells/well) in ultra-low attachment 24-well plates
(Corning). For mammosphere assays, primary MECs were
plated (2.5 × 104 cells/well) in ultra-low attachment 24-well
pates. The cell lines (treated with indicated doses of bufor-
min) and primary MECs were incubated in DMEM/F-12
medium and EpiCult-B Mouse Media (Stemcell Technolo-
gies), respectively, supplemented with 10 μg/ml insulin
(Sigma; St. Louis, MO), 1 μg/ml hydrocortisone (Sigma), 1x
B-27 (Thermo Fisher Scientific), 20 ng/ml EGF (Stemcell
Technologies), 20 ng/ml bFGF (Stemcell Technologies),
4 μg/ml heparin (Stemcell Technologies), and 50 μg/ml
Gentamycin for 7 days to form primary spheres. After
7 days, primary spheres between 40 – 120 μm in diameter
were counted and imaged before trypsinization. The har-
vested primary spheres were pipetted to form a single cell
suspension and were then replated using the same condi-
tions to form secondary spheres. Secondary spheres that
formed after 7 days of incubation were counted and imaged
for analysis. Primary and secondary sphere assays were per-
formed in at least triplicates.
Western blot analysis
Whole cell protein lysates were collected from breast cancer
cell lines or homogenized mammary tissues from 18-week-
old MMTV-erbB-2 mice. Protein concentrations were
determined using a BCA Protein assay kit (Thermo Fisher
Scientific). Fifty μg of protein were loaded in 10 or 12% SDS-
PAGE gels. Proteins were separated using gel electrophoresis
and were then transferred to nitrocellulose membranes.
Membranes were blocked in 5% milk for 2 h at room
temperature and then incubated in primary antibodies at 4 °
C overnight. After washing, the membranes were incubated
in secondary horseradish peroxidase-labeled antibodies for
1 h at room temperature. Protein bands were visualized using
SuperSignal West Pico Chemiluminescent solution (Thermo
Fisher Scientific) and imaged using a FluorChemE imager.
Whole mount analysis
Mammary glands were excised from 18-week-old MMTV-
erbB-2 mice and were placed on glass slides for fixation in
Carnoy’s solution at room temperature overnight. The
mammary glands were rehydrated with decreasing concen-
trations of ethanol for 30 min, followed by overnight stain-
ing in carmine alum stain. The next day, the stained glands
were dehydrated with increasing concentrations of ethanol,
cleared with xylene, and mounted using Permount
(Thermo Fisher Scientific). The mounted mammary glands
were imaged using a Nikon Eclipse 80i microscope and the
Nikon Elements Imaging System (Nikon Instruments, Inc.).
Histology and immunohistochemistry (IHC)
For histological and IHC analyses, formalin-fixed, paraffin-
embedded (FFPE) mammary glands from 18-week-old
MMTV-erbB-2 mice were deparaffinized and rehydrated
with xylene and ethanol, respectively. Then, for
hematoxylin and eosin (H&E) staining, the tissues were
stained with hematoxylin for 5 min, followed by separate
water, acid alcohol (1% HCl in ethanol), and 0.2% ammonia
washes. After the consecutive washes, the FFPE tissues
were stained with eosin Y for 1 min. Before mounting the
stained tissues with Permount, the tissues were dehydrated
and cleared.
For IHC, the FFPE slides were boiled in citrate buffer
(pH 6.0) for 30 min at 100 °C for antigen retrieval. Then
the slides were blocked in 3% H2O2 in methanol for
10 min at room temperature. Nonspecific binding was
blocked using 10% horse serum, followed by overnight in-
cubation in the Ki67, p-mTOR, mTOR, or p-AMPK pri-
mary antibodies at 4 °C. After the overnight incubation in
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the primary antibody, the slides were incubated in second-
ary antibody for 1 h at room temperature. The ABC re-
agent (Vector Laboratories; Burlingame, CA) and
diaminobenzidine (DAB) were used for color development
reactions in the tissues, followed by counterstaining with
hematoxylin and mounting for observational analyses.
The Nikon Eclipse 80i microscope and Nikon Elements
Imaging System Software were used to capture images of
the stained sections.
Primary MEC isolation
Mammary glands were excised from 18-week-old MMTV-
erbB-2 mice and were homogenized using a tissue chopper
(Mickle Laboratory Engineering). The dissociated tissues
were digested in collagenase (Roche) and hyaluronidase
(Sigma) at 37 °C for 2 h followed by digestion with 0.25%
trypsin-EDTA (Sigma) and dispase (Roche)/DNase I
(Sigma). The cell suspension was then filtered through a
40 μm mesh strainer, resulting in a single cell suspension
for use in the described assays [33].
Flow cytometry analysis
Isolated primary MECs were prepared for flow cytometry
analysis using primary fluorescent antibodies against CD24,
CD61, CD49f, and lineage markers according to the proto-
col used by Shelton et al. (2010) [34]. Cell populations were
gated and analyzed using FlowJo analysis software.
Statistical analysis
Statistical differences between two groups were deter-
mined using a Student’s t-test. A p-value of ≤ 0.05 was
chosen for significance in all experiments.
Results
Buformin inhibits cell proliferation and induces cell cycle
arrest in erbB-2-overexpressing breast cancer cells in vitro
Metformin has demonstrated the capability to inhibit cell
proliferation in various cancer cells, yet previous reports
have shown that phenformin and buformin have increased
biological activity than metformin [31]. We found that
buformin reduced cell viability in erbB-2-overexpressing
SKBR3 (IC50 = 246.7 μM) and BT474 (IC50 = 98.6 μM)
breast cancer cell lines (Fig. 1a). As shown in Fig. 1b, further
investigation into the cellular responses caused by buformin
revealed buformin-induced G0/G1 cell cycle arrest in SKBR3
and BT474 breast cancer cells. In both cell lines, buformin
increased the percentage of cells in G0/G1 phase and re-
duced the percentage of cells in S phase, especially in the
SKBR3 cells, which is indicative of diminished proliferating
cells. Impaired cell proliferation was also confirmed in both
cell lines, as demonstrated by the reduction in the number
of colonies formed in the clonogenic assay (Fig. 1c). To-
gether, these data provide critical proof of concept in which
buformin exhibits cell growth inhibitory effects in vitro.
Buformin diet inhibits mammary syngeneic tumor growth
in MMTV-erbB-2 transgenic mice
To further test the buformin-associated inhibitory effects
in vivo, we used a syngeneic tumor model in MMTV-
erbB-2 mice that were fed a buformin diet (1.2 g bufor-
min/kg chow) for 12 days after inoculation with 78617
breast cancer cells. Mice fed the buformin diet exhibited
significantly reduced tumor volumes and weights as
compared to the control mice (Fig. 2). These in vivo re-
sults are consistent with our in vitro data demonstrating
the anti-cancer potential of buformin.
Buformin suppresses the stemness of
erbB-2-overexpressing breast cancer cells in vitro
Increasing evidence supports a critical role of CSCs in
cancer development [35, 36]. Our lab has previously
determined that metformin targets CSC populations;
therefore, we tested the effects of buformin on the CSC
population using an ALDEFLUOR assay that detects
ALDH activity, which is a characteristic of CSCs [13, 37].
In Fig. 3a, we show that buformin significantly lowers the
percentage of ALDH+ SKBR3 and BT474 cells. Similarly,
buformin inhibited tumorsphere formation, especially of
secondary spheres of 78617, an erbB-2-overexpressing
mammary tumor-derived cell line, and BT474 cells, indi-
cating its inhibitory activity on CSC self-renewal (Fig. 3b).
Altogether, these results suggest that the regulation of the
CSC population and associated proliferative characteris-
tics are implicated in the anti-proliferative/anti-cancer
mechanism of buformin.
Buformin regulates AMPK/mTOR and RTK signaling
pathways in erbB-2-overexpressing breast cancer cells
In order to understand which signaling pathways are
regulated by buformin treatment and which may con-
tribute to the CSC population changes that we have
demonstrated, we performed Western blot analysis on
SKBR3 and BT474 cells that were treated with low-dose
(0 – 3 mM) buformin. Indeed, buformin treatment stim-
ulated typical AMPK activation/phosphorylation that re-
sulted in reduced mTOR activation/phosphorylation and
remarkable inactivation of downstream signaling mole-
cules, including p70S6K and 4EBP1 (Fig. 4a). Buformin
also suppressed RTK activation, including erbB-2 and
IGF1R signaling (Fig. 4b). Likewise, downstream Akt
activation/phosphorylation was inhibited by buformin
exposure in both cell lines. To note, SKBR3 and BT474
cells exhibited differential buformin-induced expression
of phospho-Erk1/2 and phospho-Stat3, such that their
expression was upregulated and downregulated in
SKBR3 and BT474 cells, respectively. This observation
will be further addressed in the Discussion section.
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Buformin diet during the premalignant risk window
hinders mammary morphogenesis and proliferation in
MMTV-erbB-2 transgenic mice
Extensive mammographic density and development are
preceding factors that are associated with increased breast
cancer risk [38, 39]. To determine the impact of buformin
diet on mammary morphogenesis, premalignant mammary
glands were harvested from 18-week-old MMTV-erbB-2
mice for whole mount and histological analyses. As shown
in Fig. 5a, the control mice exhibited a more dense and
complex ductal network with increased side branching, as
compared to the buformin-fed mice. These findings indi-
cate that buformin effectively impedes mammary morpho-
genesis and produces remarkable histoarchitectural
changes, which are further supported by H&E stained tis-
sues (Fig. 5b). In the H&E stained mammary tissues from
MMTV-erbB-2 mice, buformin substantially reduced the
ductal thickness and altered the epithelial cell organization
(Fig. 5b). Moreover, the percentage of proliferating cells was
significantly reduced by buformin in the mammary tissues,
as indicated by Ki67 IHC staining (Fig. 5c-d). Together, our
data demonstrate that buformin induces morphogenic
Fig. 1 Buformin induces anti-proliferative effects in erbB-2-overexpressing SKBR3 and BT474 cells. a An MTT assay was performed to compare cell
viability in SKBR3 and BT474 cells treated with buformin (0, 1, 3, 10, 30, 100, 300 μM, 1, 3, or 10 mM) for 5 days. The average viable cell fraction for each
sample (N = 8) is plotted ± standard error (S.E.). b SKBR3 and BT474 cells were treated with buformin (0, 0.5, 1, or 3 mM) for 48 h and then cell cycle
progression was measured using FACS analysis (N = 4). The average percentage of cells in G2/M, S, and G0/G1 phases of the cell cycle are graphed for
SKBR3 (left panel) and BT474 (right panel) cells. c SKBR3 and BT474 cells were treated with buformin (0, 0.2, or 1 mM) in triplicate for 14 days as part of
the clonogenic assay. Then the colonies were fixed and stained with crystal violet. The average number of colonies that formed after 14 days is
graphed. Representative images of crystal violet-stained colonies are shown in the far right panel. Values are graphed as the mean ± S.E. (**p < 0.01)
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changes in the premalignant mammary glands, which indi-
cate precursory histological phenotypes that are associated
with impeded mammary tumor development.
Buformin selectively inhibits stem cell populations and
suppresses the self-renewal of MECs from MMTV-erbB-2 mice
Since mammary stem cells (MaSCs) give rise to proliferative
luminal/progenitor cells and are precursors to CSCs, MaSCs
play a critical role in mammary gland development and
tumorigenesis [40, 41]. Therefore, we hypothesized that
buformin may impair mammary morphogenesis and ultim-
ately prevent tumorigenesis through MaSC reprogramming
and the modulation of other stem cell populations in the
premalignant mammary tissues. Recently, advances in stem
cell technology have led to improved markers, including
CD24, CD61, and CD49f cell surface markers, for individual
cell populations. Using CD24/CD49f cell markers with flow
cytometry, we were able to isolate 3 key subpopulations,
luminal cells, basal/myoepithelial cells (Myo), and mammary
reconstitution units (MRUs), found in primary MECs from
MMTV-erbB-2 mice. Luminal cells are comprised of
progenitor cells with proliferative properties, while the MRU
population are enriched with MaSCs. The myoepithelial cell
population represents basal cells. Fig. 6a indicates that the
buformin diet significantly reduced luminal and MRU popu-
lations, while shifting towards the basal/myoepithelial cell
population. Of note, buformin inhibits the overall lineage-
negative cell population as displayed in fewer cells appearing
in the representative flow cytometry plot (Fig. 6b).
According to the ‘CSC theory’, a cellular hierarchy exists
where MaSCs can give rise to self-renewing TICs, which in
turn promotes the initiation, progression, and metastasis of
breast cancer [24, 42, 43]. To characterize the specific cell
populations that contribute to tumorigenesis and are
promising anti-cancer therapeutic targets, Lo et al. (2012)
previously used CD61/CD49f cell surface markers to isolate
these cell populations and reported that the CD61high/
CD49fmid population is comprised of CSCs/TICs in erbB-2-
overexpressing mammary tumors [44]. Indeed, using
CD61/CD49f cell markers, we demonstrated that buformin
strikingly suppresses the CD61highCD49fmid population (p2)
of primary MECs from MMTV-erbB-2 mice (Fig. 7a-b).
Since buformin only induced modest changes in the other
CD61/CD49f cells populations, our data indicate that
buformin selectively targets the CSC/TIC population for
inhibition, which is consistent with our previous metformin
report [13]. Based on our current findings, we further
investigated the effects of buformin on the self-renewal
property of stem cell subpopulations in premalignant
MECs. Using a CFC assay, we determined in Fig. 8a that
the buformin diet significantly diminished the colony for-
mation as compared to the control diet. Results from the
primary mammosphere formation assay reflect a similar
trend from the CFC assay as the primary MECs from the
Fig. 2 Buformin diet inhibits syngeneic tumor growth in MMTV-erbB-2 mice. 8-week-old MMTV-erbB-2 mice were inoculated with 78617 cells and tumors
began to appear by Day 6 after the initial inoculation. At Day 6, mice (N = 7) were administered a buformin diet for 12 days with tumor palpitation every
2 days. The tumor volumes during the monitoring from Day 6 – 18 (a) and final tumor weights (b) were recorded. Representative images of tumors from
the control and buformin-fed mice are shown in c. Values are graphed as the mean ± S.E. (**p< 0.01)
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buformin-fed mice formed significantly fewer spheres as
compared to the control samples (Fig. 8b). The buformin-
stimulated changes in CSC/TIC populations and stem-like
properties of MECs indicate that buformin, like metformin,
elicits its anti-cancer responses through selective targeting
of CSCs/TICs in vitro (Fig. 3a) and in vivo (Fig. 7a-b).
Buformin diet regulates mTOR, erbB-2/PI3K/Akt, ER, and
Wnt/β-catenin signaling in mammary tissues from
MMTV-erbB-2 mice
To uncover the underlying mechanisms that contribute
to the buformin-induced changes in mammary gland
morphogenesis and stem cell populations, we analyzed
Fig. 3 Buformin suppresses the stemness of breast cancer cells in vitro. a SKBR3 and BT474 cells were treated with buformin (0, 0.5, or 1 mM) for 48 h
(N = 4). Then ALDH activity was measured using an ALDEFLUOR assay. The percentage of ALDH+ cells are presented in the graphs. b 78617 and BT474
cells were plated in ultra-low attachment plates and treated with buformin (0, 0.2, or 0.5 mM) for 7 days (N = 4). Primary tumorspheres were counted
and imaged after 7 days. Then the cells were harvested and homogenized to form a single cell suspension that was replated in ultra-low attachment
plates for another 7 days. Secondary tumorspheres were then counted and imaged. All values are graphed as the mean ± S.E. (*p < 0.05, **p < 0.01)
Fig. 4 Buformin regulates AMPK/mTOR and RTK signaling pathways in erbB-2-overexpressing breast cancer cells. SKBR3 and BT474 cells were treated with
buformin (0, 0.1, 0.3, 1, or 3 mM) for 24 h. Expression and activation/phosphorylation of the indicated proteins relating to the AMPK/mTOR (a) and RTK (b)
pathways were analyzed using Western blotting
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the expression of proteins involved in various signaling
pathways. By analyzing the AMPK/mTOR pathway, we
found that the activation/phosphorylation of down-
stream targets of mTOR, including p70S6K and 4EBP1,
were downregulated by buformin diet (Fig. 9a). Interest-
ingly, no significant changes in AMPK and mTOR acti-
vation/phosphorylation were observed in our Western
blot results (Fig. 9a). Since discrepancies may exist be-
tween cell lysate-based and in situ analyses, we further
examined the activation/phosphorylation of mTOR and
AMPK in premalignant mammary tissues using IHC.
We found that buformin diet does indeed suppress the
activation/phosphorylation of mTOR, but does not
activate AMPK (Fig. 9b, Additional file 1). Collectively,
integrated data from Western blot and in situ analyses
indicate an AMPK-independent mechanism of mTOR
inhibition, which we will address in the Discussion sec-
tion. Furthermore, the buformin diet induced an upregu-
lation of phospho-Akt and downregulation of phospho-
Erk and phospho-Stat3 in the MMTV-erbB-2 mice as
compared to the control mice (Fig. 9c). This inverse re-
sponse was consistent with the trend observed in our in
vitro model (Fig. 4b). Additionally contributing to the
anti-proliferative responses demonstrated in mammary
tissues from buformin-fed mice, phospho-ER and Cyclin
D1 were suppressed in relation to the control-fed mice
(Fig. 9d). Wnt/β-catenin pathway results indicate the
suppression of β-catenin activation, and Oct4A expres-
sion (Fig. 9e). Collectively, our signal transduction data
implicate mTOR, RTK, ER, and Wnt/β-catenin signaling
as major factors involved in the anti-proliferative mech-
anism of buformin that protects mammary tissues from
tumor development in vivo.
Discussion
Phenformin and buformin were first tested as anti-cancer
agents around the 1970s and initially demonstrated promis-
ing cancer preventative and therapeutic responses. How-
ever, lactic acidosis, a consequence of lactate buildup from
mitochondrial complex I inhibition, was a fatal side-effect
associated with phenformin and buformin treatment in
about half of the patients who developed this complication
[45]. Unfortunately, the risk of harmful side-effects out-
weighed the clinical benefits and clinical trials investigating
the anti-cancer effects of these drugs were terminated. In
the past decade, renewed interest in biguanide agents as
cancer preventative and treatment options have emerged
due to the association of metformin with cancer prevention
in Type II diabetes patients [3, 4]. To study the anti-cancer
effects of buformin, while avoiding the occurrence of
deleterious side-effects, our lab employs a method of drug
administration where buformin is added to the standard
diet of the subject animals. Our buformin diet was formu-
lated based on the study by Zhu et al. (2015) that used a
buformin diet at the same concentration (7.6 mmol bufor-
min/kg of chow) with reported plasma (1.4 ± 1.8 μmol/L)
and mammary carcinoma (6.7 ± 6.2 nmol/g) concentrations
of buformin in their animal model of breast cancer [30].
Since both our study and the study by Zhu et al. used the
same buformin concentration in the diet and demonstrated
comparable tumor inhibition, we estimate that the plasma
and tissue/tumor concentrations of buformin in our model
should also be similar to what was previously reported.
Importantly, the administration of buformin in the diet has
successfully reduced the toxicity of buformin and increased
the maximum tolerated dose in rodents [30]. Well-
tolerated administration of buformin provides the basis for
proof of concept studies that can be expanded for future
research regarding the anti-cancer efficacy of buformin and
other biguanides.
Fig. 5 Buformin diet during the premalignant risk window hinders
mammary morphogenesis and proliferation in MMTV-erbB-2 mice.
Mice were fed control and buformin diets for 10 weeks (N = 6). At
18 weeks of age, the mice were sacrificed for whole mount preparation
of mammary glands (a). Representative images of H&E stained (b) and
Ki67 immunostained (c) mammary tissues from 18-week-old mice are
shown. Brown staining in C indicates Ki67+ cells, from which the
percentage of Ki67+ cells from each group is graphed in d. All values
are depicted in the graph as the mean ± S.E. (**p < 0.01)
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Fig. 6 Buformin targets mammary stem cell populations in premalignant tissues from MMTV-erbB-2 mice. Primary MECs were isolated from 18-week-
old mice that were fed control or buformin diets for 10 weeks (N = 4). Cells were labeled with fluorescent antibodies for flow cytometry analysis of
different MEC populations. a The CD24/CD49f-probed cells produced 3 distinct cell populations, including luminal cells (left panel), myoepithelial cells
(middle panel), and MRUs (right panel) that were compared between the control-fed and buformin-fed mice. Representative images of CD24/CD49f
flow cytometry plots are shown in b. All values are depicted in the appropriate graphs as the mean ± S.E. (*p < 0.05, **p < 0.01)
Fig. 7 Buformin targets cancer stem cell/tumor-initiating cell populations in premalignant tissues from MMTV-erbB-2 mice. As detailed above, isolated
MECs were labeled with CD61/CD49f markers and analyzed with flow cytometry (N = 4). a The percentage of CD61highCD49fmid cell populations were
compared between the control and buformin-fed mice with representative CD61/CD49f flow cytometry plots shown in b. All values are depicted in
the graph as the mean ± S.E. (**p < 0.01)
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Fig. 8 Buformin impairs the stemness of primary MECs from MMTV-erbB-2 mice. a Primary MECs were plated for a CFC assay (N = 3). After 7 days, the
cells were fixed and stained as previously described. The number of colonies in the control and buformin diet samples was recorded. b Primary MECs
were used for a primary mammosphere assay where the isolated cells were plated in ultra-low attachment plates for 7 days as described previously
(N = 3). Then the primary spheres were counted. All values are depicted in the appropriate graphs as the mean ± S.E. (**p < 0.01)
Fig. 9 Buformin regulates signaling pathways that promote cell proliferation. Protein lysates were extracted from premalignant mammary tissues
of 18-week-old MMTV-erbB-2 mice that were fed control or buformin diets for 10 weeks (N = 3). The expression and activation/phosphorylation of
proteins associated with the mTOR (a-b), RTK (c), ER (d), and Wnt/β-catenin (e) pathways were examined using Western blot analysis (a, c-e) and
IHC (b). Representative images of p-mTOR and mTOR immunostained mammary tissues from 18-week-old mice are shown in b
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Previous reports on the anti-cancer efficacy of buformin
have demonstrated overall inhibitory effects in endometrial
cancer cell lines and in vivo carcinogen-induced mammary
tumor models [30, 31]; nevertheless, the anti-cancer bene-
fits specific to breast cancer and, in particular, different sub-
types of breast cancer remain limited. As such, our aim to
investigate the efficacy of buformin in various models of
erbB-2-overexpressing breast cancer, which accounts for
approximately 30% of human breast cancer cases [46], has
provided further evidence of the anti-cancer potential of
buformin. In our study, we report growth inhibition, tar-
geted suppression of putative MaSC/CSC-enriched popula-
tions, and modulation of cell stemness, as measured by
various analyses, in cellular, syngeneic, and transgenic
models of erbB-2-overexpressing breast cancer. By evaluat-
ing the molecular responses to buformin treatment, we
were able to propose several mechanisms that may contrib-
ute to the phenotypic changes that we report.
Our initial proof of concept experiments recapitulated the
anti-proliferative effects of buformin that were previously
determined by others in multiple cancer models [30, 31]. In
our current study, we demonstrated that buformin inhibited
cell growth and cell cycle progression, as analyzed by MTT,
clonogenic, and cell cycle assays (Fig. 1). Buformin, when
administered in the diet, also significantly impaired the
growth of syngeneic tumors in MMTV-erbB-2 mice (Fig. 2).
With the inhibition of major hallmarks of cancer in vitro
and in vivo, we examined the effects of buformin in the
premalignant mammary glands of MMTV-erbB-2 mice.
Buformin treatment during the ‘risk window’ for spontan-
eous tumor development in these mice resulted in signifi-
cant histoarchitectural changes, including decreased
mammary ductal density and proliferative features in the
preneoplastic mammary glands (Fig. 5). The mechanism by
which buformin induces these anti-proliferative effects may
involve several signal transduction pathways, including
AMPK, RTK, and ER pathways, that are known to play crit-
ical roles in the regulation of cell proliferation.
AMPK, an energy sensor, regulates mTOR-mediated
signaling involved in differentiation, transcription, and
translation. In response to the mitochondrial dysfunction
previously shown to be induced by buformin [47], we
observed concomitant upregulation of p-AMPK and
downregulation of p-mTOR and downstream targets,
p-p70S6K and p-4EBP1, in erbB-2-overexpressing breast
cancer cells in vitro (Fig. 4). Although the activation/
phosphorylation of AMPK was not observed in vivo
(Fig. 9a, Additional file 1), the evident suppression of
mTOR, p70S6K, and 4EBP1 activation/phosphorylation
(Fig. 9a-b) exhibited a similar trend to our in vitro sig-
naling data and is indicative of buformin-stimulated al-
terations of an AMPK-independent mTOR signaling
pathway. Several reports have similarly determined that
metformin can inhibit mTOR signaling independent of
AMPK activation in other in vitro and in vivo model sys-
tems [21, 48–51]. As such, REDD1 is an alternative
mTOR regulator that has been reported to induce
growth inhibition, cell cycle arrest, and apoptosis under
nutrient deprived conditions, including in response to
metformin treatment [21, 52]. Additionally, metformin
has been shown to suppress mTOR activity through the
upregulation of key components of the mTORC1 com-
plex, PRAS40 and RAPTOR, in glioma cell and animal
models [48]. Metformin has also been reported to sup-
press non-metastatic and metastatic canine mammary
tumor cell lines in vitro via AMPK-dependent and -inde-
pendent processes, respectively [49]. Importantly, mTOR
is downstream of RTK signaling, including erbB-2 and
IGF1R, which we have shown to be downregulated by
buformin (Fig. 9). Further studies are warranted to fully
understand the AMPK-independent mTOR inhibition by
buformin that we have demonstrated in our in vivo
mouse model.
Furthermore, previous studies have reported that
biguanides negatively regulate insulin receptor (IR) and
IR substrate (IRS), which result in IGF1R inactivation
[53, 54]. As such, our data corroborate this concept as
demonstrated by the decrease of IGF1Rα and p-IGF1R
upon buformin treatment in the MMTV-erbB-2 mice,
despite variations of IRS expression and phosphorylation
between animals (Fig. 9). Importantly, IGF1R can form
heterotrimers with multiple EGFR family members, in-
cluding erbB-2 [55]. Metformin can disrupt the inter-
action of IGF1R and erbB-2 as well [27]. In our study,
we demonstrate that buformin repressed erbB-2 activa-
tion alongside downstream inhibition of PI3K/Akt activ-
ity. Interestingly, buformin inversely modulated the
phosphorylation of Akt and Erk1/2 in the SKBR3 cell
line and MECs collected from MMTV-erbB-2 mice, but
not BT474 cells (Fig. 4 and 9). Other reports using rapa-
mycin, an mTOR inhibitor, on pancreatic cancer cells
and metformin on NSCLC cells have also revealed dif-
ferential effects on Akt and Erk activation, thus indicat-
ing a feedback mechanism involving mTOR and RTK
signaling [56, 57]. Alternatively, the parallel decrease in
p-Akt and p-Erk1/2, as we noted upon buformin treat-
ment in BT474 cells, is supported by several recent re-
ports, indicating that these inconsistencies in Akt and
Erk activation may be cell-type specific [58].
Other signaling pathways, such as the ER pathway, regu-
late cellular growth and survival responses. In this context,
we report that buformin inhibited ER activation/phosphoryl-
ation and downstream signaling of Cyclin D1 in vivo (Fig. 9).
The regulation of these pathways is critical in erbB-2-
overexpressing breast cancers due to IGF1R and/or erbB-2
crosstalk with ER [59, 60].
In addition to the inhibitory effects on mammary tumor
growth, buformin also elicits substantial inhibition of cell
Parris et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:28 Page 12 of 15
populations associated with putative MaSCs (MRU popula-
tion) and CSCs/TICs (ALDH+/CD61highCD49fmid cells) in
erbB-2-overexpressing breast cancer cell lines and primary
MECs from preneoplastic mammary glands of MMTV-
erbB-2 mice (Fig. 3, 6, and 7). Since MaSCs are integral for
mammary gland development, mammary morphogenesis is
also associated with MaSCs/CSCs. Suppressed MaSC and
CSC populations (Fig. 6–7) are consistent with impeded
mammary morphogenesis induced by buformin (Fig. 5).
Importantly, the selective targeting of CSCs, as we show in
our studies, is a promising preventative/therapeutic strategy
to block pro-oncogenic events that contribute to cancer ini-
tiation in premalignant tissues and the progression of can-
cer at various stages.
The key to developing CSC/TIC inhibitors is to under-
stand the underlying mechanisms that result in selective
inhibition of CSC/TIC populations, as demonstrated by
buformin in our models of erbB-2-overexpressing breast
cancer. As a potentially critical pathway for the CSC-
targeted effects of buformin, the Wnt/β-catenin pathway
plays a substantial role in the regulation of numerous
pro-cancerous cellular responses, including cell differen-
tiation and proliferation [61, 62]. Our in vivo data indi-
cates that buformin blocks the activation of β-catenin
and other downstream signaling molecules (i.e. Oct4A)
(Fig. 9), providing a potential connection between the
differential epithelial subpopulations that we report in
the buformin-treated samples as compared to the
control-treated samples (Fig. 6–7). Due to the concur-
rent reduction in the CD61highCD49fmid cell population
and mammosphere formation efficiency in the MECs
from buformin-treated mice, our results suggest that
buformin may be inducing Wnt/β-catenin-mediated
MaSC reprogramming to deter the differentiation into
CSCs. This proposed mechanism would explain the se-
lective targeting of CSCs by metformin, as previously
published in our lab, and buformin [13].
Conclusions
Taken together, we have demonstrated novel cancer in-
hibitory effects of buformin, especially on putative
MaSCs/TICs, in premalignant mammary tissues. Our re-
sults also indicate that the erbB-2-overexpressing sub-
type of breast cancer may be more susceptible to the
anti-cancer effects of buformin, due to the inhibition of
numerous signaling molecules associated with RTK, es-
pecially erbB-2, signaling pathways. Our study has fur-
ther clinical impact as demonstrated by the well-
tolerated administration of buformin in the diet to avoid
the previously reported toxic side effects, which im-
proves the overall drug safety profile of buformin and
paves the way for future preclinical and clinical investi-
gation of buformin and other biguanides as cancer
preventative and treatment options.
Additional file
Additional file 1: Buformin does not upregulate AMPK activation in
MMTV-erbB-2 mice. Representative images of p-AMPK immunostained
mammary tissues from 18-week-old MMTV-erbB-2 mice that were fed
control or buformin diets for 10 weeks are shown. (TIF 789 kb)
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